Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zoledronic acid
Drug ID BADD_D02392
Description Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Indications and Usage Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.[L13712,L13715,L13721] Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.[L13712,L13715,L13721]
Marketing Status approved
ATC Code M05BA08
DrugBank ID DB00399
KEGG ID D01968; D08689
MeSH ID D000077211
PubChem ID 68740
TTD Drug ID D0VM2L
NDC Product Code 63415-0532; 0078-0435; 25021-826; 55150-266; 67457-619; 68083-142; 14593-836; 63850-7104; 82920-012; 63323-966; 69367-190; 65372-1117; 17478-327; 71288-806; 62147-0125; 68554-0037; 16729-242; 43598-330; 55150-283; 67457-794; 68001-437; 65129-1144; 0143-9642; 63323-961; 68083-116; 68083-135; 0409-4215; 16714-815; 67457-390; 68083-256; 63126-906; 43598-331; 70860-210; 72266-152; 42533-102; 53104-7622; 65797-0006; 43598-255; 25021-801; 54288-100; 57741-2600; 25021-830; 55111-685; 55111-688
UNII 6XC1PAD3KF
Synonyms Zoledronic Acid | 2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid | CGP 42446A | CGP-42446 | CGP 42446 | CGP42446 | CGP-42'446 | CGP42'446 | CGP 42'446 | Zometa | Zoledronic Acid Anhydrous | Zoledronate
Chemical Information
Molecular Formula C5H10N2O7P2
CAS Registry Number 118072-93-8
SMILES C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urine abnormality20.02.01.0130.002863%-
Urticaria10.01.06.001; 23.04.02.001--
Uveitis06.04.03.003; 10.02.01.0230.038363%
Varicose vein24.10.04.001---
Vasculitis10.02.02.006; 24.12.04.0270.004294%
Vein disorder24.03.02.015---
Ventricular extrasystoles02.03.04.0070.004294%-
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.0100.058690%
Visual acuity reduced06.02.10.012; 17.17.01.0110.017178%
Visual impairment06.02.10.0130.065561%-
Vitamin B12 deficiency14.12.02.0040.004294%-
Vitamin D deficiency14.12.03.0030.002863%-
Vitreous detachment06.09.01.002; 12.01.04.0050.005726%-
Vocal cord paralysis17.04.06.002; 22.04.01.002--
Vomiting07.01.07.0030.215864%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Yellow skin08.01.03.046; 09.01.01.009; 23.03.03.0420.004294%-
Tubulointerstitial nephritis20.05.02.0020.018609%-
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.027484%-
Fibromyalgia15.05.02.002---
Musculoskeletal disorder15.03.05.025---
Intracardiac thrombus02.11.01.017; 24.01.05.0030.002863%-
Infusion site erythema08.02.05.008; 12.07.05.009; 23.03.06.016---
Poor venous access24.03.02.0170.009734%-
Underweight14.03.02.017---
Hypoacusis04.02.01.006--
Onychoclasis23.02.05.0050.012883%-
The 17th Page    First    Pre   17 18 19 20 21    Next   Last    Total 26 Pages